Take your place alongside CDMO / CMO makers of Small and Large Molecule Finished Drugs
In North America, approximately 4,100 small molecule drugs are in various stages of development. At the same time nearly 1,000 new large molecule drugs are in various stages of development representing a quarter of all North American drug development activity.
The North American market has a plethora of opportunities for CDMO / CMO companies. In addition, the biopharmaceutical market is growing at an 11% CAGR representing strong future opportunity.
The U.S. pharmaceutical market accounts for approximately 40% of the global market. In 2014, 6 out of the top 11 companies were US based. And more than 3,000 pharmaceutical and medical device companies, employing over 100,000, are in the immediate vicinity of Philadelphia where CPhI North America will be held in 2017.
CPhI North America will deliver companies interested in finished formulation and biopharmaceuticals.
- At the CPhI Worldwide event in 2015, 26% of the attendees at CPhI Worldwide were interested in finished formulation
- 15% focused on Large Molecule Biopharmaceuticals
- 47% of the attendees, in general, held CEO, VP, Director, or GM titles
Companies who are already participating in FDF include:
- Merck - Millipore